title: Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis.
abstract: Antiretroviral-based HIV-1 prevention strategies - including antiretroviral treatment (ART) to reduce the infectiousness of individuals with HIV-1 and oral and topical pre-exposure prophylaxis (PrEP) for uninfected individuals to prevent HIV-1 acquisition - are the most promising new approaches for decreasing HIV-1 spread. Observational studies among HIV-1 serodiscordant couples have associated ART initiation with a reduction in HIV-1 transmission risk of 80-92%, and a recent randomized trial demonstrated that earlier initiation of ART (that is, at CD4(+) T-cell counts between 350 and 550 cells/mm(3)), in the context of virological monitoring and adherence support, resulted in a 96% reduction in HIV-1 transmission. A number of ongoing and recently-completed clinical trials have assessed the efficacy of PrEP for HIV-1 prevention as pericoitally administered or daily-administered 1% tenofovir gel and daily oral tenofovir disoproxil fumarate (TDF) and combination emtricitabine (FTC)/TDF. Completed studies have demonstrated HIV-1 protection efficacies ranging from 39% to 75%. However, two trials in African women have shown no HIV-1 protection with TDF and FTC/TDF PrEP; the reasons for lack of efficacy in those trials are being investigated. Adherence is likely the key to efficacy of antiretrovirals for HIV-1 prevention, both as ART and PrEP. Critical unanswered questions for successful delivery of antiretroviral-based HIV-1 prevention include how to target ART and PrEP to realize maximum population benefits, whether HIV-1-infected individuals at earlier stages of infection would accept ART to reduce their risk for transmitting HIV-1 and whether highest-risk HIV-1-negative persons would use PrEP, and whether high adherence could be sustained to achieve high effectiveness.
authors.affiliation: Department of Global Health, University of Washington, Seattle, USA. ccelum@uw.edu
authors.forename: Connie
authors.initials: C
authors.lastname: Celum
authors.forename: Jared M
authors.initials: JM
authors.lastname: Baeten
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1; D006801:Humans; D011292:Premedication; D011634:Public Health
chemical_list: D019380:Anti-HIV Agents